Major US laboratory network to carry Biocept’s flagship liquid biopsy tests

Biocept Inc (NASDAQ:BIOC) announced Monday that a major laboratory-management provider now offers the company’s flagship liquid biopsy tests for patients with cancer.

The company said that Beacon Laboratory Benefit Solutions Inc, or BeaconLBS, connects physicians and their patients to its Labs-of-Choice network, which are preferred, high-quality laboratories that now including Biocept.

BeaconLBS also administers laboratory benefit management programs for health plans to improve test-ordering efficiency, test appropriateness, affordability, and quality of care for health-plan members, according to statement. 

READ: Biocept shares jump after supplier of liquid biopsy tests wins patent in China

Biocept offers the biopsy tests commercially to doctors, hospitals, clinics and researchers and are used to test and monitor for lung, breast, gastric, colorectal and prostate cancers – which represent 45% of all metastatic cancers – as well as melanoma.

The San Diego-based company says the simple blood tests obtain the needed molecular information non-invasively and more rapidly than a tissue biopsy.

“We are very pleased to become a laboratory services provider for BeaconLBS, which offers innovative laboratory management technology solutions that benefit physicians, patients and payers,” said Biocept CEO Michael Nall.

“As a BeaconLBS Lab-of-Choice, more patients will have an opportunity to benefit from our liquid biopsy testing platforms, which can help physicians identify actionable biomarkers in patients diagnosed with cancer and design personalized treatment programs in order to improve outcomes.” 

Biocept’s stock recently traded up 4% to $1.06 a share in New York.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Story by ProactiveInvestors